Heidy King-Jones - 22 Mar 2022 Form 4 Insider Report for Provention Bio, Inc.

Role
Chief Legal Officer
Signature
/s/ Thierry Chauche, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
22 Mar 2022
Net transactions value
$0
Form type
4
Filing time
24 Mar 2022, 18:01:44 UTC
Previous filing
20 Jan 2022
Next filing
23 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVB Stock Option (right to buy) Award $0 +60,000 +40% $0.000000 210,000 22 Mar 2022 Common Stock, par value $0.0001 60,000 $11.23 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously reported on a Form 4 filed on August 3, 2020, on August 3, 2020 the Reporting Person was granted a stock option for 300,000 shares of Common Stock, 120,000 of which option shares vest in four equal annual installments commencing on August 3, 2021 and 180,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 60,000 of the 180,000 performance option shares on March 22, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 60,000 option shares.
F2 The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.
F3 Represents the 120,000 time-based option shares referred to in footnote (1) plus the 30,000 vested performance option shares which vested August 3, 2021 plus the 60,000 vested performance options shares referred to in footnote (1).